Intercept Pharmaceuticals (ICPT) said Tuesday that an experimental medicine to treat the fatty liver disease known as NASH achieved its primary goal in a Phase 3 clinical trial, giving it a shot at becoming the first drug to treat the condition and turning it into a potential blockbuster commercial opportunity.
Based on the data collected from the clinical trial, Intercept said it would file marketing applications for the treatment in the U.S. and Europe in the second half of the year. The drug is called obeticholic acid, or OCA.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
This is a really good news!! I hope this gets approved and successful, so that liver transplant can be avoided. Fatty liver diseases is at a rise in the US more and the main reason behind is binge drinking as alcohol is the driving force behind cirrhosis.
Source- https://www.myhealthyclick.com/alcoholic-fatty-liver-disease-on-rise-in-the-us-finds-study
Intercept stock was up more than 25% in the pre-market session after this positive data. But when the market opened that momentum was missing. https://news.alphastreet.com/intercept-pharmaceuticals-icpt-stock-surges-52-week-high-positive-data-from-liver-fibrosis-due-to-nash-drug-study/